



September 2, 2015

Dear Manufacturers:

I am writing on behalf of Maine Medical Center (MMC; 340B ID DSH 200009) to inform manufacturers MMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of MMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, MMC qualified for the 340B Program as a disproportionate share hospital and has participated in the 340B Program since July 1, 2011.

Through the audit process, MMC was found to have non-compliance within their 340B Program and responsible for possible repayment as a result of the following finding(s):

***“Finding 1: MMC was billing Medicaid contrary to information contained in the HRSA Medicaid Exclusion File. This action may have resulted in duplicate discounts as prohibited by 42 USC 256b(a)(5)(A).”***

Maine Medical Center (MMC) contacted the State of Maine Medicaid Agency (MaineCare) and the State Medicaid Agency has confirmed duplicate discounts did not occur.

MMC has identified all affected manufacturers and will contact each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from MMC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Jack Schifano, 340B Project Specialist, Maine Medical Center, 22 Bramhall Street, Portland, Maine 04106, [SCHIFJ@MMC.ORG](mailto:SCHIFJ@MMC.ORG), 207-662-7086 .

Sincerely,

Lugene A. Inzana,  
Senior Vice President, Finance, and Chief Financial Officer  
Maine Medical Center  
22 Bramhall Street  
Portland, Maine 04102